entertainment -WSS

entertainment

author：explore 2025-09-30 22:27:46 - browse：653

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

WSS

STAT Readout Newsletter: Biotech news today

Hospitals owned by private equity see complications spike 25%

Why health records don't always know when patients are dead

Violet CEO on training clinicians to promote more inclusive care

Is there really a nursing shortage in the U.S.?

Keeping primary care docs in field isn't impossible, says AAFP CEO

focus

entertainment

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

State Dept. review finds Biden bears some blame for Afghanistan failures

Violet CEO on training clinicians to promote more inclusive care

State Dept. review finds Biden bears some blame for Afghanistan failures

CZI to create biohub to build anti

Tori Bowie and the unacceptable rates of Black maternal death

SEC charges former device maker CEO with $41 million fraud

The cancer drug shortage isn’t new — and neither are the solutions

Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Merck, Daiichi strike cancer drug pact worth up to $22 billion

What STAT readers think about the FDA and patient advocacy

What STAT readers think about the FDA and patient advocacy

Roche drug slashes death risk in early

Roivant's CEO is a star, but biotech's black hole persists

focus

explore

Wikipedia

hotspot